Alnylam Pharmaceuticals
ALNY
#650
Rank
NZ$69.58 B
Marketcap
NZ$521.22
Share price
2.04%
Change (1 day)
-2.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): NZ$1.50 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$4.28 Billion. In 2025 the company made an earning of NZ$1.12 Billion, an increase over its 2024 earnings that were of -NZ$0.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.50 B33.69%
2025 NZ$1.12 B-369.48%
2024 -NZ$0.42 Billion-24.59%
2023 -NZ$0.56 Billion-67.84%
2022 -NZ$1.73 Billion36.93%
2021 -NZ$1.26 Billion-8.04%
2020 -NZ$1.37 Billion-15.66%
2019 -NZ$1.63 Billion12.23%
2018 -NZ$1.45 Billion62.91%
2017 -NZ$0.89 Billion17.78%
2016 -NZ$0.76 Billion43.44%
2015 -NZ$0.53 Billion60.69%
2014 -NZ$0.33 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$97.17 Million27.48%
2010 -NZ$76.22 Million-10.92%
2009 -NZ$85.57 Million95.77%
2008 -NZ$43.71 Million
2006 -NZ$70.02 Million-9.13%
2005 -NZ$77.06 Million34.74%
2004 -NZ$57.19 Million36.79%
2003 -NZ$41.81 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$27.97 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$13.57 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$9.14 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$1.25 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$84.07 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.29 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$4.02 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.61 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA